Rosacea Marketed and Emerging Pipeline Drugs Assessment, 2023 | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Rosacea Marketed and Emerging Pipeline Drugs Assessment, 2023 | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Rosacea therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Rosacea Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Rosacea Market. 

The Rosacea Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Rosacea Pipeline Analysis

Rosacea Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Rosacea and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Rosacea market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  


Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Rosacea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical


Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy


Learn How the Ongoing Clinical & Commercial Activities will Affect the Rosacea Therapeutic Segment @


Rosacea Therapeutics Landscape

There are approx. 25+ key companies which are developing therapies for Rosacea. Currently, Sol-Gel Technologies is leading the therapeutics market with its Rosacea drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Rosacea Therapeutics Market Include:

  • Sol-Gel Technologies

  • Maruho Co., Ltd.

  • AOBiome LLC

  • CAGE Bio Inc.

  • Dermata Therapeutics

  • BioMimetix JV, LLC

  • Dr Reddys Laboratories

  • Amgen

  • Alfasigma

  • AiViva BioPharma

  • BioPharmX, Inc.

  • Botanix Pharmaceuticals

  • Evommune

  • Tarus Pharmaceuticals

  • Cellix Bio.

  • Fortress Biotech

  • AOBiome

And many other 

Rosacea Drugs Covered in the Report Include:

  • Epsolay: Sol-Gel Technologies

  • M 1220: Maruho Ltd

  • BMX-010: BioMimetix

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Rosacea Current Treatment Patterns

4. Rosacea – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Rosacea Late Stage Products (Phase-III)

7. Rosacea Mid-Stage Products (Phase-II)

8. Rosacea Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Rosacea Discontinued Products

13. Rosacea Product Profiles

14. Key Companies in the Rosacea Market

15. Key Products in the Rosacea Therapeutics Segment

16. Dormant and Discontinued Products

17. Rosacea Unmet Needs

18. Rosacea Future Perspectives

19. Rosacea Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States